Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397348 | 1.00 | CYP1A2 (0.42) | CYP1A2CTSBCTSSCTSKMME | |
| SCHEMBL7272157 | 0.84 | CYP1A2 (0.61) | CYP1A2MMEFOLH1 | |
| SCHEMBL7290672 | 0.84 | CYP1A2 (0.61) | CYP1A2MMEFOLH1 | |
| SCHEMBL399275 | 0.82 | CYP1A2 (0.44) | CYP1A2MMEFOLH1 | |
| SCHEMBL400641 | 0.79 | CYP1A2 (0.61) | CYP1A2CTSBCTSSCTSKMME | |
| SCHEMBL400642 | 0.79 | CYP1A2 (0.61) | CYP1A2CTSBCTSSCTSKMME | |
| SCHEMBL1814454 | 0.77 | CYP1A2 (0.50) | CYP1A2FOLH1 | |
| SCHEMBL397390 | 0.77 | FOLH1 (0.68) | FOLH1 | |
| SCHEMBL1818938 | 0.77 | CYP1A2 (0.50) | CYP1A2FOLH1 | |
| SCHEMBL6171750 | 0.76 | TAAR1 (0.47) | CYP1A2FOLH1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101665-B2 | Process for synthesis of tritiated and deuterated thiorphan and acetorphan | ROCHE PALO ALTO LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110319656-A1 | PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN | ROCHE PALO ALTO LLC | 2011-12-29 | — | — | US | disclosed |
| WO-2009077386-A1 | PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319656-A1 | PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN | NAT1, ZRANB2, TXN | CYP1A2 91/4885CTSB 430/4885CTSS 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.